1. Home
  2. STXS vs IKT Comparison

STXS vs IKT Comparison

Compare STXS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • STXS
  • IKT
  • Stock Information
  • Founded
  • STXS 1990
  • IKT 2008
  • Country
  • STXS United States
  • IKT United States
  • Employees
  • STXS N/A
  • IKT N/A
  • Industry
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • IKT Biotechnology: Pharmaceutical Preparations
  • Sector
  • STXS Health Care
  • IKT Health Care
  • Exchange
  • STXS Nasdaq
  • IKT Nasdaq
  • Market Cap
  • STXS 151.3M
  • IKT 139.0M
  • IPO Year
  • STXS 2004
  • IKT 2020
  • Fundamental
  • Price
  • STXS $2.11
  • IKT $2.08
  • Analyst Decision
  • STXS
  • IKT Buy
  • Analyst Count
  • STXS 0
  • IKT 2
  • Target Price
  • STXS N/A
  • IKT $8.00
  • AVG Volume (30 Days)
  • STXS 224.8K
  • IKT 123.6K
  • Earning Date
  • STXS 05-12-2025
  • IKT 05-14-2025
  • Dividend Yield
  • STXS N/A
  • IKT N/A
  • EPS Growth
  • STXS N/A
  • IKT N/A
  • EPS
  • STXS N/A
  • IKT N/A
  • Revenue
  • STXS $27,510,000.00
  • IKT N/A
  • Revenue This Year
  • STXS $25.90
  • IKT N/A
  • Revenue Next Year
  • STXS $60.57
  • IKT N/A
  • P/E Ratio
  • STXS N/A
  • IKT N/A
  • Revenue Growth
  • STXS 1.50
  • IKT N/A
  • 52 Week Low
  • STXS $1.54
  • IKT $1.12
  • 52 Week High
  • STXS $2.72
  • IKT $4.20
  • Technical
  • Relative Strength Index (RSI)
  • STXS 57.13
  • IKT 52.37
  • Support Level
  • STXS $2.07
  • IKT $1.95
  • Resistance Level
  • STXS $2.17
  • IKT $2.16
  • Average True Range (ATR)
  • STXS 0.10
  • IKT 0.18
  • MACD
  • STXS -0.00
  • IKT 0.01
  • Stochastic Oscillator
  • STXS 80.03
  • IKT 66.67

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Share on Social Networks: